1. Home
  2. |Insights
  3. |NHTSA Proposes Rule on Safe Deployment of Self-Driving Vehicles

NHTSA Proposes Rule on Safe Deployment of Self-Driving Vehicles

Client Alert | 1 min read | 03.24.21

In a recently published RAIL, The Journal of Robotics, Artificial Intelligence & Law article, “NHTSA Proposes Rule on Safe Deployment of Self-Driving Vehicles,” Crowell & Moring’s Rebecca Baden Chaney and Rukiya Mohamed discuss the National Highway Traffic Safety Administration’s (NHTSA) advance notice of proposed rulemaking that marks a departure from the way in which the agency has previously addressed automated driving systems (ADS), and automotive safety more generally. Although NHTSA does not intend to issue any Federal standards around ADS yet, the agency is considering how it can use regulatory authority to place a focus on safety measures as ADS technology develops. This article outlines NHTSA’s proposed safety framework and possible implementation of that framework.

The authors note that NHTSA is seeking comments from the public through April 1, 2021 with the goal of developing a “safety framework” to “define, assess, and manage the safety of ADS performance while ensuring the needed flexibility to enable further innovation.”

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...